Strategies For Developing Bioanalytical Method For Certain Oral Antidiabetics | 6060
ISSN: 2155-9872

Journal of Analytical & Bioanalytical Techniques
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Strategies for Developing Bioanalytical Method for Certain Oral Antidiabetics

International Conference & Exihibition On Analytical and Bioanalytical Techniques - 2010

Janardhanan Bagyalakshmi

ScientificTracks Abstracts: J Anal Bioanal Techniques

DOI: 10.4172/2155-9872.1000001

The International Diabetes Federation estimates that 285 million people around the world have diabetes. This total is expected to rise to 438 million within 20 years. Each year a further 7 million people develop diabetes. Around 90 % of the diabetes patients are found to suffer from type 2 diabetes mellitus. Many patients suffering from type 2 diabetes require treatment with more than one antihyperglycemic drug to achieve optimal glycemic control. The combination of metformin hydrochloride � Biguanides with any one of the Sulphonylureas - glipizde, gliclazide, glibenclamide, glimperide or with Alpha glucosidase inhibitors - voglibose can present daunting challenges to analytical scientist during HPLC analysis. This talk will drill into the details of method development and discuss the common problems encountered as in case of metformin & sulphonyl urea � vast differences in their polarity, pk a , makes extraction from the biological fluids very difficult which may lead to low recovery and low sensitivity. Differences based on their protein binding characteristics - sulphonyl urea strongly bound to proteins lead to low recovery. Strategies to optimize the mobile phase, extraction procedures in biological fluids, to increase the recovery by disrupting drug- protein binding will be highlighted. Challenges to improve the detection of low UV absorbing component as in the case of voglibose will be dealt. These methods are inevitable to monitor a population of diabetic patients who take several diabetic medications without changing HPLC colums.